Abstract 857
Background
Colonoscopy is recommended as preferred test for first-degree relatives (FDRs) of colorectal cancer (CRC) patients. However, colonoscopy screening rate remains low. A systematic review and meta-analysis conducted by the research team show that tailored communication is an effective approach to increase uptake of colonoscopy. However, the decision rules that guide the tailored process remain unclear. Based on the identified evidences, a mHealth intervention with an integrated tailoring decision system was developed. This study aimed to test the feasibility and acceptability of this mHealth intervention in Chinese FDRs.
Methods
A single-blinded, family-based cluster randomized controlled trial was conducted. 20 families with CRC patients were randomized to intervention (10 families, n = 11) or control group (10 families, n = 10). Intervention consists of 3 sessions that provided tailored cancer and screening messages on response of personal assessment. All participants received an e-brochure on CRC and CRC screening. Feasibility was measured by recruitment and completion rate, whereas acceptability was assessed by a self-developed questionnaire.
Results
34.5% of eligible family members agreed to participate. 70% of participants completed the trial and all of them completed 3 sessions. All the participants satisfied with the intervention, and agreed the intervention help them understand their risks and appropriate screening recommendations. The main reason for low recruitment rate is that cancer cases were contacted through phone to identify FDRs. Even this is a common strategy when conducting family trials, it is difficult to obtain the trust of FDRs by phone due to the adverse influence of phone scam.
Conclusions
It is acceptable to provide mHealth intervention to Chinese FDRs. However, family recruitment utilizing cancer registry-identified cases seems less feasible in Chinese population. Recruitment through direct contact with FDRs is recommended, for example, through current screening program or clinical units. Furthermore, a definitive trial to test the effectiveness of developed intervention is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bai Yang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract